# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
-8-K
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 3...
Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Can...